Sign in

Prof Tom John

@drtomjohn.bsky.social
1.2K followers 1.2K following 45 posts

Thoracic medical oncologist Peter Mac All expressed views are my own Musician (mayhemtom) - debut album now on Spotify Mayhemtom.com.au linktr.ee/mayhemtom

PostsRepliesMedia
Prof Tom John @drtomjohn.bsky.social · 18/04/2026
Proud to be part of this new podcast series with @DrAlexAdjei, where we provide insights into some of the key papers from @JTOonline. JTO Insights: April 2026 jto.org/audio-do/jto-i… @IASLC Available on all streaming platforms:podcasts.apple.com/au/podcast/j...91open.spotify.com/episode/3NYf...lg
podcasts.apple.com
JTO Insights: April 2026
Podcast Episode · JTO Insights · 16 April · 29min
020
Prof Tom John @drtomjohn.bsky.social · 13/10/2025
Happy to share this paper from one of our #Swiss residents @PeterMacCC: Does IO given in #SCLC up front impact responses and survival in subsequent lines of therapy? Sadly the answer was no, chemo outcomes were similar to that seen pre-IO. Maybe BiTES? authors.elsevier.com/c/1lw8qcYZOi...
authors.elsevier.com
040
Prof Tom John @drtomjohn.bsky.social · 06/09/2025
Looking forward to playing with @drsanjaypopat.bsky.social - a lot of fun rehearsing covers and @mayhemtomi tracks. Check us out tonight @iaslc.bsky.social #wclc2025
1113
Prof Tom John @drtomjohn.bsky.social · 05/09/2025
So much fun rehearsing some acoustic tunes with @drsanjaypopat.bsky.social - don’t forget to stick around after the #WCLC25 plenary tomorrow evening @iaslc.bsky.social
050
Prof Tom John @drtomjohn.bsky.social · 05/09/2025
Looking forward to playing some tunes with my good friend and musician @drsanjaypopat.bsky.social tomorrow at #WCLC25. Make sure you stick around at the welcome reception Saturday evening!
060
Prof Tom John @drtomjohn.bsky.social · 15/07/2025
Loving this @mayhemtomi track, a lovely collaboration with @dean_fennell on synths. Inspired by the “Pale blue dot speech” from Carl Sagan. Check it out on all streaming platforms details here: mayhemtom.com.au
mayhemtom.com.au
Melbourne Oncologist-Turned-Musician: Songs of Love, Burnout, and Grief
Discover the moving music of a Melbourne oncologist who channels experiences of love, burnout, and grief into powerful songs. A unique journey from the world of medicine to creating heartfelt, soulful...
000
Reposted by Prof Tom John
Prof Shalini Vinod @shalinivinod.bsky.social · 04/06/2025
🙏🏽 ABC for shining the light on 🇦🇺 deadliest cancer. Bring on #lungcancer screening www.abc.net.au/news/2025-06... @abcnewsbot.bsky.social @gerryhanna.bsky.social @drtomjohn.bsky.social @dkarikios.bsky.social @bensolomon1.bsky.social
abc.net.au
Australia's deadliest cancer to get new screening program
After years of lobbying from patients, the first ever national lung cancer screening program will roll out next month for people who have a significant history of smoking.
062
Reposted by Prof Tom John
Prof Shalini Vinod @shalinivinod.bsky.social · 29/04/2025
🇦🇺 guidelines for #lungcancer screening. Screening coming 1st July. Great step forward in #lungcancer Mx. Spread the word. www.health.gov.au/our-work/nlc... @newsgp.bsky.social @ausgov.bsky.social @drtomjohn.bsky.social @bensolomon1.bsky.social @dkarikios.bsky.social
health.gov.au
032
Prof Tom John @drtomjohn.bsky.social · 20/05/2025
If you’re interested in where #lungcancer vaccines are at relative to #melanoma, check out this @togaanz.bsky.social podcast with @gvlongphdmd.bsky.social and Ken OByrne. podcasts.apple.com/au/podcast/v... open.spotify.com/episode/0OJb...
open.spotify.com
Vaccines in Thoracic Oncology: The Next Frontier in Immunotherapy
Conversations in Lung Cancer Research · Episode
052
Prof Tom John @drtomjohn.bsky.social · 15/05/2025
Fantastic work to get this happening 🙌🏾🙌🏾🙌🏾
010
Reposted by Prof Tom John
Mark Dawson @mafdawson.bsky.social · 15/05/2025
Australia completely lacks a dedicated training program for clinician scientists. With the vision and support of VMIAL @petermaccc.bsky.social is extremely proud to announce the first clinician-scientist fellowship. If you meet the eligibility criteria PLEASE APPLY! www.nature.com/naturecareer...
nature.com
Clinician Scientist Fellowship - Parkville, Melbourne (AU) job with Peter MacCallum Cancer Centre – Parkville | 12839522
Peter Mac is launching Australia’s first clinician-scientist fellowship to advance cancer care, fostering innovation and global collaboration.
12310
Prof Tom John @drtomjohn.bsky.social · 30/04/2025
Close to releasing first single from new album. If you’re interested please presave it. Presaves help the #spotifyaunz and #applemusic algorithm figure out how hot a #indie #indiemusic track might be. gyro.to/Atheistic
gyro.to
Atheistic
Listen to content by Mayhemtom.
040
Reposted by Prof Tom John
Hidehito HORINOUCHI @hhorinouchi.bsky.social · 22/03/2025
🔥 @natmedicine.bsky.social 🆙 ✅Molecular residual disease analysis of adj osimertinib in resected EGFR-mutated stage IB–IIIA NSCLC 🎯MRD preceded imaging DFS by a median of 4.7 🩸RaDaR MRD analysis 👥 Dr. Roy Herbst @drtomjohn.bsky.social #LCSM @oncoalert.bsky.social www.nature.com/articles/s41...
nature.com
Molecular residual disease analysis of adjuvant osimertinib in resected EGFR-mutated stage IB–IIIA non-small-cell lung cancer - Nature Medicine
Exploratory post hoc analysis of molecular residual disease from the ADAURA trial of adjuvant osimertinib in patients with resected EGFR-mutated stage IB–IIIA non-small-cell lung cancer shows that mol...
042
Prof Tom John @drtomjohn.bsky.social · 19/03/2025
It’s in the paper. Median follow up time from randomisation was 44.2 months in Osi arm and 19.1 months in placebo. Median follow up post Osi was 11.7months
100
Prof Tom John @drtomjohn.bsky.social · 19/03/2025
My concern with this is that CNS was a common site of recurrence and there is morbidity and mortality associated. Nuanced discussion with patient re: toxicity vs waiting. I suspect most of my pts would take Osi, but close surveillance also very reasonable.
110
Prof Tom John @drtomjohn.bsky.social · 19/03/2025
Random chance from small numbers. But note that baseline is post surgery +/- chemo. More likely MRD+ if higher stage and also MRD+ effectively is St4, as on cessation of Osi, all MRD+ recurred
140
Prof Tom John @drtomjohn.bsky.social · 19/03/2025
I think these data highlight the relevance of MRD assays in guiding treatment decisions esp in oncogene driven tumours. This may mean longer duration of therapy though.
110
Prof Tom John @drtomjohn.bsky.social · 19/03/2025
MRD RaDaR assay was 65% sensitive and 95% specific. The co-mutation data are also interesting. TP53 seems to also be associated with poorer outcomes in early stage disease #NSCLC #Earlystage @petermaccc.bsky.social
100
Prof Tom John @drtomjohn.bsky.social · 19/03/2025
In this study we found that very few pt developed MRD positivity on Osi, but on cessation of Osi 17% developed MRD+ and most within 12mo of stopping
100
Prof Tom John @drtomjohn.bsky.social · 19/03/2025
Honoured to co-first author this important paper with Prof Herbst and the entire team looking at MRD in the ADAURA trial. www.nature.com/articles/s41...
nature.com
Molecular residual disease analysis of adjuvant osimertinib in resected EGFR-mutated stage IB–IIIA non-small-cell lung cancer - Nature Medicine
Exploratory post hoc analysis of molecular residual disease from the ADAURA trial of adjuvant osimertinib in patients with resected EGFR-mutated stage IB–IIIA non-small-cell lung cancer shows that mol...
1126
Reposted by Prof Tom John
Patrick Forde @patrickforde.bsky.social · 19/02/2025
Great day for lung cancer care!. Addition of just 3 cycles of nivolumab immunotherapy to standard neoadjuvant chemo leads to improved overall survival for surgically resectable lung cancer! Just a press release for now but full data upcoming! #lcsm news.bms.com/news/corpora...
news.bms.com
Bristol Myers Squibb Announces Opdivo® Plus Chemotherapy as the First and Only Neoadjuvant-Only Immuno-Oncology Therapy to Demonstrate Statistically Significant and Clinically Meaningful Overall Survi...
Bristol Myers Squibb (NYSE: BMY) today announced the final analysis of overall survival (OS) from the Phase 3 CheckMate -816 study, which evaluated Opdivo ® (nivolumab) in combination with platinum-do...
0145
Reposted by Prof Tom John
Tom Newsom-Davis @tnewsomdavis.bsky.social · 19/02/2025
Non KRAS G12C mutations an important unmet need in lung cancer: we see them often, including in non-smokers Nice work here highlighted by @drtomjohn.bsky.social We hope to open 1L RMC-6236 trial at Chelsea & Westminster later this year
041
Prof Tom John @drtomjohn.bsky.social · 19/02/2025
Congratulations to Adel from @petermac for this analysis showing KRAS G12D patients are more likely to be non-smokers but also associated with low PDL1, comutations with TP53/STK11 and derive limited immunotherapy response. Area of need for targeted Rx #LCSM smex-ctp.trendmicro.com/wis/clicktim...
smex-ctp.trendmicro.com
0133
Reposted by Prof Tom John
Lauren Julia Brown @laurenjbrown.bsky.social · 18/02/2025
*New Publication* led by Dr Adel Shahnam from @petermaccc.bsky.social in Lung Cancer Poorer survival outcomes in patients with KRAS G12D mutations receiving immunotherapy. Novel targeted therapies should be examined in detail for this population. www.lungcancerjournal.info/article/S016... #lcsm
lungcancerjournal.info
Real-World outcomes of Non-Small cell lung cancer patients harbouring KRAS G12C and KRAS G12D mutations
The Kirsten rat sarcoma oncogene homolog (KRAS) is one of the most frequently mutated oncogenes in non-small-cell lung cancer (NSCLC), occurring in approximately 30 % of cases [1]. KRAS mutations are ...
041
Reposted by Prof Tom John
Physicians for a Healthy Democracy @physiciandemocracy.medsky.social · 01/02/2025
Kamala Harris-Black history is American history.  Our music, art, sports, literature, leadership, resistance, and resilience are fundamental to the fabric of our nation and the progress that we fight for.  This month and every month, we celebrate Black history, and we continue our fight for justice and equality for every American.
546077
Prof Tom John @drtomjohn.bsky.social · 30/01/2025
www.theguardian.com/commentisfre...
theguardian.com
We are seeing anti-medical, anti-science narratives everywhere – how can doctors like me respond? | Mariam Tokhi
Medical practitioners are no longer trusted instinctively, with sometimes devastating consequences. How do we engage with people who mistrust us?
000
Prof Tom John @drtomjohn.bsky.social · 08/01/2025
Thank you Professor! You and Jonathan Cebon were the inspiration and mentorship behind me getting here!
120
Prof Tom John @drtomjohn.bsky.social · 08/01/2025
Yes it is the balance of OS benefit with AEs that will be critical. Then there is also the degree of benefit compared with FLAURA2 - where OS benefit has trended
110
Prof Tom John @drtomjohn.bsky.social · 05/01/2025
Lovely day at the #pinktest #mcgrath day in #sydney, India vs Australia.
0171
Reposted by Prof Tom John
TOGA @togaanz.bsky.social · 10/12/2024
HIT IT WITH YOUR BEST SHOT 👊 Catch our latest podcast on IO in early-stage NSCLC in the Australian context. Apple: buff.ly/3ZgBePP Spotify: buff.ly/3Ze0I0c
131
Reposted by Prof Tom John
TOGA @togaanz.bsky.social · 29/11/2024
Lung cancer is the leading cause of cancer death in women. Don't ignore the signs! Thanks for coming on the journey with us this #LungCancerAwarenessMonth Find out more > buff.ly/3YG2OWB #LCAM
042
Reposted by Prof Tom John
TOGA @togaanz.bsky.social · 04/12/2024
Time is running out to join us for the Kosi Climb with Prof Nick Pavlakis! Together, we can make an impact. Don't miss your chance to make a difference and be part of something special! Registrations close soon. Find out more > buff.ly/3Tov4LA
021
Reposted by Prof Tom John
Danny Rose @danny-rose.bsky.social · 08/12/2024
Having trouble thinking of a Christmas gift for someone? Go to ChatGPT and type in a summary of the person, a price range, and ask for gift ideas. List (with links) will follow. Tell others to do this for the gifts you will receive. Let’s (let AI) raise the standard of gift giving this Xmas!
021
Prof Tom John @drtomjohn.bsky.social · 05/12/2024
Excellent summary from @donnadlubsky.social I really think we should be taxing these industries more. The amount of money wasted on supplements could be used to help fund trials and treatments that are proven to work. www.theguardian.com/commentisfre...
theguardian.com
Multivitamins promise glowing skin, better sleep and a longer life. But who do supplements really benefit? | Donna Lu
For healthy people, pills, patches and gummies just create ‘expensive urine’. But for those with nutrient deficiencies, vitamin supplements have clear benefits
232
Reposted by Prof Tom John
Kate Sears @katesears.bsky.social · 01/12/2024
KEAP1-NRF2 pathway and expression of antioxidant genes, H/T: @angelifriedmann.bsky.social
073
Reposted by Prof Tom John
Oncogene Cancer Research @oncogenecancer.bsky.social · 25/11/2024
With every new #lungcancer research finding, we move the needle for those impacted. It's why Dr @gerryhanna.bsky.social believes that LC research is improving care for patients in real time – we’re shifting the dial! Let's continue this. #BecauseofResearch #LCAM @younglungcancer.bsky.social
0227
Prof Tom John @drtomjohn.bsky.social · 23/11/2024
Whoops!
000
Prof Tom John @drtomjohn.bsky.social · 23/11/2024
@melmoore.bsky.social @togaanz.bsky.social @prunellab.bsky.social @bensolomon1.bsky.social
120
Prof Tom John @drtomjohn.bsky.social · 23/11/2024
Always wonderful to be part of the #TOGAPreceptorship going through the main papers that determine how we treat #NSCLC today. Excellent presentations and discussions. But the best part is catching up with good mates! The future of thoracic oncology is bright 🌟
2231
Reposted by Prof Tom John
Vivek Subbiah, MD @viveksubbiah.bsky.social · 16/11/2024
@oncoalert.bsky.social Starter pack Easy 👉🏼one click & followed all go.bsky.app/GKXp9Fy
2186
Prof Tom John @drtomjohn.bsky.social · 22/11/2024
😂😂😂🤣😂
110
Prof Tom John @drtomjohn.bsky.social · 22/11/2024
media.tenor.com
a woman says " i 'm your number one fan " while looking down
ALT: a woman says " i 'm your number one fan " while looking down
150
Reposted by Prof Tom John
Lung Cancer Research Foundation @lcrf.org · 21/11/2024
#LungCancer survival rates rose 22% from 2015 to 2019. While promising, we want to see those numbers go much higher…while we're at it, let's shoot for 10, 15, 20 or more years. Learn how you can make an impact this Lung Cancer Awareness Month: buff.ly/4eDVXTo. #LCAM2024
Graphic showing an increase in 5-year lung cancer survival rates by 22% from 2015 to 2019. Features silhouette figures representing people, with Lung Cancer Research Foundation logo and website LCRF.org/LCAM.
1224
Reposted by Prof Tom John
Jarushka Naidoo @drjnaidoo.bsky.social · 19/11/2024
Sharing a fledgling #LCSM starter pack for those joining Bluesky 🦋 #Medsky #Oncsky @oncoalert.bsky.social go.bsky.app/MjDxbG2
65220
Reposted by Prof Tom John
Paul Kaiser @paulkaiser.bsky.social · 20/11/2024
Where have all the doctors gone? www.medpagetoday.com/special-repo.... #digitalintervention #socialsky
medpagetoday.com
Physicians Flock to Bluesky, Hoping to Leave X Behind
Many compare it to the early days of Twitter
072
Reposted by Prof Tom John
Jarushka Naidoo @drjnaidoo.bsky.social · 18/11/2024
'TrialGPT' A new chatGPT for clinical trials @natureportfolio.bsky.social: - 3 steps: TrialGPT-Retrieval, TrialGPT-Matching, TrialGPT-Ranking - Retrieval identified 90% suitable trials - 42% time-saving in matching a patient to a trial Like, wow #MedSky #OncSky #LCSM www.nature.com/articles/s41...
nature.com
Matching patients to clinical trials with large language models - Nature Communications
Patient recruitment is challenging for clinical trials. Here, the authors introduce TrialGPT, an end-to-end framework for zero-shot patient-to-trial matching with large language models.
16925
Prof Tom John @drtomjohn.bsky.social · 19/11/2024
Hey @bsky.app can you do something about following people back? Current system is slow and clunky!
040
Prof Tom John @drtomjohn.bsky.social · 18/11/2024
Don’t think they’re up yet, but I’ll prompt them. Great idea for #TOGApreceptorship
020
Prof Tom John @drtomjohn.bsky.social · 17/11/2024
Thanks Amy! 🫶
010
Prof Tom John @drtomjohn.bsky.social · 17/11/2024
Warm night at St Paul’s cathedral Bendigo last night, playing with @lindamileshkin . Lovely acoustics, no mics, some amazing singers and instrumentalists. Thanks for having me @bendigo_health #melbournemusic #indiemusic #livemusic
170